Background: We previously showed that newborns congenitally infected with Trypanosoma cruzi (M+B+) display a strong type 1 parasite-specific T cell immune response, whereas uninfected newborns from T. cruzi-infected mothers (M+B2) are prone to produce higher levels of proinflammatory cytokines than control neonates (M2B2). The purpose of the present study was to determine if such fetal/neonatal immunological environments could alter the response to standard vaccines administered in early life.
Introduction
Infectious diseases are a leading world-wide cause of morbidity and mortality in childhood, against which vaccination remains the best prevention measure [1] . However, protection induced by vaccines is of limited effectiveness in early life owing to the relative immaturity of the neonatal immune system. Moreover, the fetal/ neonatal immune system is initially polarized toward a Th2 immune environment which appears essential for the survival of the fetus [2, 3] . Indeed, both dendritic cells and T cells present quantitative and qualitative defects in the neonatal period, limiting the development of CD4+ Th1 cell responses essential for the control of intra-cellular pathogens [2, 3] , as well as the production of antibody responses [4] . Nonetheless, neonates are in some cases able to develop mature T cell responses. This has been demonstrated in congenital infections with Trypanosoma cruzi [5] and cytomegalovirus (CMV) [6] , in infection with Bordetella pertussis in early life [7] , and after early vaccinations with Bacillus Calmette-Guerin (BCG) [8] or the whole cell pertussis vaccine [9, 10] . Additionally, BCG vaccination at birth has been shown to increase both cellular and humoral responses to other vaccines such as hepatitis B and poliomyelitis vaccines [10] . Active maternal infections may also modulate neonatal immune responses to vaccines, as demonstrated in newborns of mothers chronically infected with helminths, who developed a Th2-biased response to BCG vaccination, by contrast with those born to non-infected mothers [11, 12] . The modulation of immune responses to vaccines in infants from mothers infected with intracellular parasites, and having experienced such congenital infection has heretofore not been investigated.
Chagas disease, or American trypanosomiasis, caused by the protozoan parasite Trypanosoma cruzi, is a major cause of morbidity and mortality in Latin America where 8-10 million people are currently estimated to be infected [13] . It has also become an important health issue in the United States and Europe due to large-scale migration of Latin Americans over the last few decades [14] . The parasite is primarily transmitted by insect vectors (in endemic areas of Latin America), blood transfusion and congenitally (in all areas) [15] . Even the frequency of transmission by vectors and blood transfusion decreases as a result of vectorial control programmes and improvement of blood bank screening, mother-to-child transmission of T. cruzi presently cannot be prevented and has thus become an important route of transmission [16] . Recent estimations indicate that at least 15,000 newborns are likely to be congenitally infected with T. cruzi each year in Latin America [17] and 2,000 in North America [18] . In Europe, such transmission also becomes a problem in migrants originating from endemic countries [19] [20] [21] . In Bolivia, a highly endemic area for Chagas disease, we have reported that 17% of pregnant women are chronically infected with T. cruzi and that congenital transmission occurs in 5 to 6% of the cases [22] . We have showed that congenitally infected newborns develop a parasite-specific T cell immune response comparable to that of adults [5] as well as phenotypic and functional modifications of their NK cells [23] . On the other hand, newborns of T. cruzi-infected mothers are prone to produce higher levels of pro-inflammatory cytokines in comparison to those born to non-infected mothers [24] . The present study aimed to determine if such modifications of the immune environment in infected or uninfected newborns of T. cruziinfected mothers could modulate immune responses to vaccines administered at birth or in early life. Cellular and/or humoral responses to BCG, hepatitis B virus (HBV), diphtheria and tetanus vaccines were compared in infants living in Bolivia.
Methods

Patients and diagnosis of T. cruzi infection
Two different patient groups from Cochabamba (Bolivia) were enrolled in this study: one of neonates (born at the German Urquidi Maternity) and one of infants (6 to 7 months old; followed at the Manuel Ascenci Villaroel paediatric Hospital and the Viedma Universitary Hospital, UMSS). The scientific/ethic committee of the Universidad Mayor de San Simon (UMSS) approved the study, and informed written consent was obtained from the mothers before blood collection. Maternal T. cruzi infection was assessed by standard serological techniques. T. cruzi infection in neonates and infants was diagnosed by detection of parasites in umbilical cord or peripheral blood by microscopic examination of heparinized microhematocrit tubes, or in some cases by hemoculture, as previously described [16, 22] . Congenital infection was assessed at or close to birth for 28 neonates and 10 infants. For 3 other infants, T. cruzi infection was diagnosed later on when they presented at 6-7 months old at the consultation. Congenital infection was inferred because these infants lived in an area free of vectorial transmission, had not travelled in endemic areas, and had not received blood transfusion.
Three groups of neonates and infants were established: congenitally-infected (M+B+); non-infected born to T. cruziinfected mothers (M+B2); and uninfected controls born to uninfected mothers (M2B2). A total of 68 newborns and 60 infants were included in the study (M+B+: 28 newborns and 13 infants; M+B2: 19 newborns and 36 infants; M2B2: 21 newborns and 11 infants).
Mothers of neonates and infants included in the study were all asymptotic, even when infected with T. cruzi. They originate from the same rural region surrounding Cochabamba and live in similar socioeconomic environment. The sex ratio in all groups of newborns or infants was similar (data not shown). Clinical data of the newborn groups have been previously reported [22] and Table 1 shows mean ages and weights at the time of blood collection, as well as historical clinical data at birth, of newborn and infant groups. At the time of blood collection, the infant age in the 3 groups was comparable and M+B2 and M2B2 infants were all asymptomatic. At birth, such infants had similar APGAR scores and maturity parameters. However, M+B+ infants presented at birth slightly lower mean gestational age, weight and APGAR scores; three of them showed one or two symptoms known to be associated with congenital T. cruzi infection (i.e., splenomegaly, anasarca and petechia). When examined at 6 to 7 months, M+B+ infants were asymptomatic, but had still slightly lower mean weight as compared to the other infants.
Management of patients
As soon as the diagnosis of congenital T. cruzi infection was established, treatment of infected neonates/infants (7-10 mg/kg/ day of benznidazole for 30 days, [22] ) was proposed to the mother. From the 13 M+B+ infants under study, 9 were treated within the
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two first months after birth, and 4 remained untreated at 6-7 months of age when blood was collected for the present immunological study. One remained untreated since her mother refused the treatment, and 3 were treated from 6-7 months old onwards since the diagnosis of infection was not established previously (see above). Cure was confirmed in treated cases by the subsequent negative results of direct parasitological examination (microhematocrit tubes) and T. cruzi serology. All M2B2 and M+B2 infants presented with negative serology for T. cruzi at 6 to 7 months of age, indicating that they had not acquired the infection after birth.
Vaccination programme
In accordance with the recommended Bolivian vaccination programme, all newborns received the BCG vaccine (BCG, Serum Institute of India Ltd) at birth by intradermic injection. Infants were then vaccinated against diphtheria, tetanus, whooping cough, hepatitis B and type B Haemophilus influenzae (Hib) by receiving intramuscular injections of Tritanrix mixed with Hiberix (GlaxoSmithkline Biologicals, Rixensart, Belgium) at the ages of 2, 4 and 6 months. At the same time, they also received the oral vaccine against poliomyelitis (attenuated vaccine, trivalent OPV, Sanofi Pasteur, Paris, France). Infants included in this study have all received the BCG at birth. At the time of blood sampling, 53.5% of the infants had completed the vaccinal schedule (3 doses of Tritanrix + Hiberix + OPV), the others having received 2 doses. The proportion of infants having received the 3 doses was similar in each group.
Collection of blood samples, cell isolation and in vitro cultures
Cord blood (CB) and infant peripheral blood (PB) were collected in sterile endotoxin-free heparinized tubes. Plasma was stored at 220uC until use for determinations of antibody levels. Mononuclear cells (CBMC and PBMC) were immediately isolated by Nycoprep density gradient centrifugation (Nycomed Pharma AS, Oslo, Norway). CBMC and PBMC (2610 6 cells/mLduplicates) were then cultured in RPMI containing 10% fetal calf serum (Biowhittaker, Lonza, Verviers, Belgium), either alone to measure spontaneous production of cytokines, or in the presence of one of the following antigens: tuberculin purified protein derivative of M. tuberculosis (PPD; 5 mg/mL; batch RT49, Statens Seruminstitut, Denmark), diphtheria toxoid (DT; 10 mg/mL), tetanus toxoid (TT; 10 mg/mL), or the surface S antigen of HBV (HbsAg; 10 mg/mL). DT, TT and HbsAg were kindly provided by GlaxoSmithkline Biologicals (Rixensart, Belgium). A positive control for T lymphocyte stimulation was included by incubating cells with the staphylococcal enterotoxin B (SEB; 10 ng/mL; Sigma-Aldrich) activating non specifically T cells (superantigen). After 6 days of culture at 37uC in 5% CO 2 humidified air, cell cultures were centrifuged and supernatants conserved at 270uC for further cytokine analysis.
Cytokine determinations
IFN-c and IL-13 cytokine concentrations were used as markers of Th1/Th2 responses, respectively. Cytokine levels were measured in culture supernatants by ELISA using commercial kits (IFN-c: antibody pairs and standard from Biosource, Invitrogen, Merelbeke, Belgium; IL-13: ultrasensitive kit from Bender Medsystems, VWR International, Leuven, Belgium). Standards were non-glycosylated recombinant cytokines (Biosource and Bender Medsystems). Detection limits were 2 pg/mL for IFN-c, and 1 pg/mL for IL-13. Spontaneous release of cytokines by unstimulated cells was generally undetectable or very low. In the latter case, cytokine concentration was subtracted from levels obtained after stimulation with SEB or vaccine antigens.
HbsAg, TT and DT-specific antibody determinations
IgG antibodies against HbsAg, DT and TT were measured in plasma samples by ELISA using commercial kits (HbsAg: Diasorin, Brussels, Belgium, DT and TT: Genzyme Virotech GmbH, Rüsselsheim, Germany). Results in international units (IU) were derived from WHO standard sera provided with the kits. Antibody concentrations above 10 IU/mL for hepatitis B, and 0.1 IU/mL for diphtheria and tetanus were considered to be protective [25] [26] [27] .
IgG sub-classes against HbsAg were measured by ELISA as follow : Nunc Maxisorp plates (VWR) were coated with HbsAg (GSK Biologicals) at a concentration of 1.5 mg/mL in PBS overnight at 4uC. After blocking with 1% bovine serum albumin (BSA) in PBS for 2h at 37uC, plasma samples were diluted in PBS containing 0.3% BSA and 0.05% Tween 20 and incubated for 2h at 37uC. Sample dilutions were 1/50 for IgG1 and 1/10 for other IgG sub-classes. Mouse monoclonal antibodies specific for the Fc fragment of each human IgG subclass (clones HP6001, HP6014, I7260 and HP6050 for anti-IgG1, G2, G3 and G4 antibodies respectively, Sigma-Aldrich, Bornem, Belgium) were diluted 1/ 500, and then incubated for 1h at 37uC, followed by rat monoclonal antibodies specific for mouse IgG coupled to horseradish peroxidase (clone LO-MK-1, Imex, UCL, Brussels, Belgium) at 1 mg/mL for 1h at 37uC. After each step, plates were washed with PBS containing 0.05% Tween 20. Finally, substrate and chromogen were added (hydrogen peroxide and 3,39, 5,59 tétraméthylbenzidine, BD Biosciences, Erembodegem-Aalst, Belgium) and absorbance at 450 nm was measured after 30 min colour development and stopping the reaction with 2N sulphuric acid. Positive and negative internal controls were added in each ELISA plate in order to correct the absorbances for plate variability. We found a very good correlation between the levels of total HbsAg-specific IgG measured with this ELISA and those obtained using the commercial Diasorin kit (r = 0.842, p,10
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, n = 25). Absorbances lower than 0.01 were considered a negative result.
Expression of results and statistical analysis
Results were expressed either as arithmetic means6SEM or geometric means. Statistical comparisons of concentrations of cytokine or antibody levels between groups of newborns or infants were performed either with the Mann Whitney test or by two-way analysis of variance (ANOVA), followed by Tukey test for multiple comparisons. Comparisons of proportions were carried out using the Fisher exact test. Statistical analyses were conducted using GraphPad Prism software (GraphPad Prism 4, San Diego, CA) or the Statistical Software Package SPSS version17.0.
Results
Congenitally T. cruzi-infected newborns display a polarized Th1 response to SEB Fig. 1 shows that, upon SEB stimulation, cells from M+B+ newborns produced significantly more IFN-c in comparison with the M2B2 neonate group (geometric means 4372 and 551 pg/ mL respectively). Interestingly, such congenitally infected neonates displayed at birth comparable levels to those observed in controls at 6-7 months (geometric means in M2B2 infants : 4726 pg/ mL). Meanwhile, IL-13 levels remained similar in all neonate groups. Comparable results were seen in the M+B2 and M2B2 groups. This indicates that the in utero immune environment associated with congenital Chagas disease induces an early shift in the neonatal immune response toward a type 1 response.
Congenitally T. cruzi-infected infants present a Th1 shifted response to vaccines against diphtheria, tetanus and HBV IFN-c and IL-13 were not detected at birth when CBMC were incubated with DT, TT and HbsAg vaccinal antigens. However, as shown in Table 2 , these cytokines were detected in 6 to 7 month old infants. Two way Anova followed by a test for multiple comparisons (Tukey) indicated that the IFN-c responses in the different infant groups was not influenced by the used antigen M2B2 : p = 0.007 ; M+B+ vs. M+B2 : p = 0.0003) whereas they were similar between M2B2 and M+B2 infants (p.0.05). Thus, M+B+ infants produced meanly 10-12 times more IFN-c to HbS and DT, and 3-4 times more of this cytokine in response to TT. IL-13 release to these 3 vaccinal antigens did not differ between groups. This highlights a trend towards a type 1 response for vaccines against hepatitis, diphtheria and tetanus administered in congenitally infected neonates. Since the benznidazole treatment received by M+B+ infants before vaccination might have some confounding effect on stimulating immune responses [28] , data were also analyzed separating treated and untreated infants (at the time of blood collection). Similar results were observed in both M+B+ subgroups (data not shown).
Congenitally T. cruzi-infected infants produce higher antibody levels against HbsAg in response to HBV vaccination
As indicated in Fig. 2 , mean levels of IgG antibodies against the vaccinal antigens HbsAg, DT, TT at birth were similar in the 3 groups of neonates, and high enough to be considered protective (67 to 100% above the protection thresholds of 10 IU/mL for hepatitis B, and 0.1 IU/mL for diphtheria and tetanus). This indicates that mothers had been immunized and that the transfer of such maternal antibodies during pregnancy was not affected by T. cruzi infection.
In the 3 infant groups, HbsAg-specific antibody levels were significantly higher than in newborns. This sustains HbsAg-specific antibodies to be produced by the infants in response to vaccination, although maternally transmitted antibodies may still be present at low levels their sera [29] . Inversely, DT-and TTspecific antibody levels were lower in infants than at birth, suggesting that maternally transmitted antibodies may have restricted their production [30] . Nevertheless, they are close to antibody levels described by others in vaccinated infants [31] . Interestingly, M+B+ infants produced noticeably more antibody in response to the vaccine against hepatitis than those of the other groups. Though not statistically significant, a similar trend was seen for the M+B+ DT-and TT IgG antibodies. For the reasons mentioned above, M+B+ HbsAg-specific antibody levels were also analyzed by separating treated and untreated infants, and, again, results were similar in both M+B+ subgroups (data not shown).
Since the polarization of the immune response is known to modulate the isotypes of antibodies produced [32] [33] [34] , we next determined the IgG subclass profile of the HbsAg-specific antibodies in vaccinated M+B+ infants. As shown in Fig. 3 and as expected from previous reports [35, 36] , IgG1 was the main subclass of IgG antibody found in infants vaccinated against HBV regardless of the group. Comparisons between groups show that M+B+ infants harboured 2 to 4-fold higher levels of IgG1, IgG2 and IgG3 than infants of the other groups, while IgG4 levels remained low in all groups. Such variations likely account for the greater production of total HbsAg-specific IgG described above in these M+B+ infants, likely reflecting their stronger type 1 immune environment.
Uninfected infants born to T. cruzi-infected mothers display an amplified type 1 response to PPD after BCG vaccination
We also studied the Th1/Th2 cytokine responses to the BCG vaccine by stimulating mononuclear cells with mycobacterial PPD. CBMC (newborns) did not produce either IFN-c or IL-13 after PPD stimulation, regardless of group (a total of 32 newborns were tested). By contrast, PBMC from most infants having received the BCG vaccine at birth produced cytokines in response to PPD (Fig. 4) . The proportions of IFN-c responders was $70% and similar in the 3 infant groups. However, M+B2 but not M+B+ infants, produced on average 5-fold more IFN-c in response to PPD in comparison to control M2B2 infants. IL-13 levels produced by M+B2 infants in response to PPD were low, and the proportion of IL-13 responders was slightly but significantly inferior to that of both other groups. This suggests that, even in the absence of congenital T. cruzi transmission, the maternal-fetal immune environment associated with maternal infection contributes to enhance the Th1 response to the BCG vaccine administered at birth.
Discussion
We have investigated the effect of congenital Chagas disease and/or maternal T. cruzi infection on immune responses to standard vaccines regularly administered in neonates and infants in Bolivia. Our results show that: i) congenitally T. cruzi-infected newborns (M+B+) display an early ability to produce the type 1 cytokine IFN-c; ii) their specific responses (M+B+) to the hepatitis B vaccine, and to a lesser extend to diphtheria and tetanus vaccines, administered later after birth are characterized by higher levels of IFN-c and/or protective IgG antibodies; and iii) noninfected infants born to T. cruzi-infected mothers (M+B2) secrete higher amounts of IFN-c in response to BCG vaccination administered at birth.
The responses to PPD that we observed in BCG-vaccinated infants were Th1-oriented in the 3 studied groups. This agrees with previous observations showing that BCG vaccine given at birth induces a strong Th1 response that modulates the neonatal Th2 immune environment, with the CD4+ subpopulation of T cells being the main source of IFN-c [8, 37] . However, M+B2 infants mounted a still stronger Th1 response to BCG. This likely relates to the prenatal activation of the immune system induced by maternal T. cruzi infection described by us and others, leading to a non-specific activation of various cell types as monocytes, lymphocytes and probably other cells [24, 38] . Such activation might result from the transplacental transfer of soluble molecules released by parasites present in the infected mother, such as the Tc52 molecule known to activate directly dendritic cells or proinflammatory glycophosphatidyl-inositol anchors [39] [40] [41] . Our study shows that chronic maternal infection with an intracellular pathogen can influence the neonatal immune environment sufficiently to enhance the Th1 regular infant response to BCG. This is also in line with other work showing, conversely, that neonates born to mothers chronically infected by helminths, known to promote Th2 immune responses, display diminished responses to PPD [11, 12, 42] . By contrast, M+B+ infants failed to exhibit an increased response to BCG vaccine. This is surprising, since they presented at birth, when BCG was administered, a marked type 1 immune bias (indicated by their increased IFN-c response to SEB), and harboured high amounts of circulating live parasites [43] , susceptible to release the pro-inflammatory molecules mentioned above. Different hypotheses could explain such divergence between M+B2 and M+B+ infant responses to BCG. First, the treatment received by M+B+ infants might have contributed to modify their response; the similar PPD responses observed in treated and untreated infants may not rule out a treatment effect since the number of cases in each subgroup was low. The M+B+ IFN-c2producing T cells might also have been temporary exhausted as indicated by their high level of apoptosis resulting from their intense response to parasite multiplication [5] , subsequently limiting the responses to other antigens, as also shown in other infections [44, 45] . Another possibility relates to the higher frequency of prematurity and low birth weights in the M+B+ newborn group [22] , known to reinforce immune immaturity [46, 47] . Furthermore, congenital T. cruzi infection might have down-regulated the cord blood T cell response, as observed in malaria [48] . Finally, it is also possible that the IFN-c response to BCG increases earlier in M+B+ infants than in other groups, and is no more detected at 6-7 months, in agreement with the observation that there is no more difference in the response to SEB between groups at 6-7 months.
Nevertheless, the immune responses of M+B+ infants to hepatitis B vaccine, and to a lesser extend against diphtheria and tetanus vaccines, given after birth, were stronger and more type 1-oriented than in both of the other groups of uninfected infants. This group produced significantly higher specific IgG levels in response to HBV vaccine. A similar trend was observed for antibody responses to diphtheria and tetanus vaccines. Enhanced antibody responses in M+B+ infants were associated with increased IFN-c production in response to vaccine antigens. The observation that, amongst the HbsAg-specific IgG, the IgG1, IgG2 and IgG3 subclasses, known to be associated with type 1-responses to intracellular pathogens [32] [33] [34] were increased still emphasizes the Th1-biased profile of the response. The mechanism of such type 1-shift of the immune response to DT, TT and HBV vaccines associated with congenital Chagas disease, and why it is not observed in M+B2 infants, remains to be elucidated. Some non-exclusive factors might be considered. First, the fact that the immunological modulation observed at birth in M+B2 newborns is transient [38] could imply that it could have a short term impact on immune responses to vaccines given from 2 months of age onwards. Secondly, the benznidazole treatment received by M+B+ infants might release parasitic pro-inflammatory molecules (see above) from lysed parasites favouring IFN-c production [28] . However, high parasite levels were no longer present at the time of diphtheria, tetanus and HBV vaccine administration (2, 4 and 6 months). No differences in the IgG and IFN-c responses to DT, TT and HBV antigens were observed between treated and untreated infants, suggesting that treatment has a minimal effect on the Th1 shift observed in M+B+ infants. Third, the type of vaccine might also play a role on the different responses between M+B+ and M+B2 infants. Indeed, BCG is a cellular, live attenuated vaccine, meaning that non virulent mycobacterias multiply in the host receiving the vaccine, which induces mainly a T cell response (CD4+ Th1 and CD8+), whereas the vaccines against hepatitis B, diphtheria and tetanus are acellular vaccines eliciting mainly a B cell production of IgG antibodies with the help of T cells. Our results suggest that at birth, the immune environment in uninfected newborns from T. cruzi-infected mothers (M+B2) favours preferentially a cellular response, while that of congenitally-infected infants (M+B+) is more prone to modulate antibody responses.
If the increased competence to secrete IFN-c in both M+B2 and M+B+ infants might confer better or earlier protection against infection may be discussed. Indeed, our study was limited to blood samples collected from infants at 6-7 months of age. Earlier sample collection would be useful for kinetic studies to appreciate a possible earlier protective effect. A follow-up might also permit to compare the functional implication of the protective effect of the different vaccinations between infant groups. Though the response to PPD does not correlate with protection against tuberculosis [49] , we may assume that it reflects a globally better response to BCG, a vaccine known to limit the severity of tuberculosis if acquired during early infancy, although it does not prevent the acquisition of infection [50] . For the other vaccines, the fact that M+B+ infants produce higher amounts of protective antibodies suggests that protection is probably reached earlier in life in infants suffering from congenital Chagas disease.
Although this study involved a limited number of cases, our results show that both maternal infection with T. cruzi and congenital Chagas disease have no major impediment on vaccinal responses to BCG, hepatitis B, diphtheria and tetanus vaccines in the neonatal period. Nevertheless, both conditions induced a trend towards a type 1 immune polarization known to be essential in fighting intracellular pathogens [3] . In addition, our results also show that the overcoming of immunological immaturity by T cruzi infection in early life is not limited to the development of parasitespecific immune response [5] , but has also effects on responses to parasite-unrelated vaccinal antigens. This suggests adjuvant properties of some T. cruzi molecules, offering new prospects in neonatal vaccinology.
